Clinical features of patients with anti-melanoma differentiation-associated gene-5 antibody-positive dermatomyositis complicated by spontaneous pneumomediastinum

[1]  Shiju Chen,et al.  Efficiency of Therapeutic Plasma-Exchange in Acute Interstitial Lung Disease, Associated With Polymyositis/Dermatomyositis Resistant to Glucocorticoids and Immunosuppressive Drugs: A Retrospective Study , 2019, Front. Med..

[2]  M. Takemura,et al.  Differential clinical features of patients with clinically amyopathic dermatomyositis who have circulating anti-MDA5 autoantibodies with or without myositis-associated autoantibodies. , 2018, Respiratory medicine.

[3]  K. Isoda,et al.  Evaluation of clinical prognostic factors for interstitial pneumonia in anti-MDA5 antibody-positive dermatomyositis patients , 2018, Modern rheumatology.

[4]  C. Lau,et al.  Spontaneous pneumomediastinum in a dermatomyositis patient with anti‐melanoma differentiation‐associated gene‐5 antibody and interstitial lung disease despite an initial response to immunosuppressant , 2017, International journal of rheumatic diseases.

[5]  F. Furukawa,et al.  Clinically amyopathic dermatomyositis with rapidly progressive interstitial pneumonia: The relation between the disease activity and the serum interleukin‐6 level , 2017, The Journal of dermatology.

[6]  K. Masahiko,et al.  A case of anti-MDA5-positive rapidly progressive interstitial lung disease in a patient with clinically amyopathic dermatomyositis ameliorated by rituximab, in addition to standard immunosuppressive treatment , 2017, Modern rheumatology.

[7]  M. Fujimoto,et al.  Antimelanoma differentiation‐associated protein 5 antibody level is a novel tool for monitoring disease activity in rapidly progressive interstitial lung disease with dermatomyositis , 2017, The British journal of dermatology.

[8]  C. Oddis,et al.  Anti–Melanoma Differentiation–Associated Gene 5 Is Associated With Rapidly Progressive Lung Disease and Poor Survival in US Patients With Amyopathic and Myopathic Dermatomyositis , 2016, Arthritis care & research.

[9]  M. Fujimoto,et al.  Clinical Utility of an Enzyme-Linked Immunosorbent Assay for Detecting Anti-Melanoma Differentiation-Associated Gene 5 Autoantibodies , 2016, PloS one.

[10]  O. Küçükşahin,et al.  A Case of Amyopathic Dermatomyositis with Pneumomediastinum and Subcutaneous Emphysema , 2015, Case reports in rheumatology.

[11]  Lingyun Sun,et al.  Clinical and serological features of patients with dermatomyositis complicated by spontaneous pneumomediastinum , 2015, Clinical Rheumatology.

[12]  経世 三森,et al.  抗MDA5（melanoma differentiation-associated gene 5）抗体と皮膚筋炎・急速進行性間質性肺炎 , 2013 .

[13]  Christian R. Millett,et al.  Amyopathic dermatomyositis complicated by pneumomediastinum. , 2013, The Journal of clinical and aesthetic dermatology.

[14]  M. Akiyama,et al.  Limitations of a single-point evaluation of anti-MDA5 antibody, ferritin, and IL-18 in predicting the prognosis of interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis , 2013, Clinical Rheumatology.

[15]  S. Yamasaki,et al.  The diagnostic utility of anti-melanoma differentiation-associated gene 5 antibody testing for predicting the prognosis of Japanese patients with DM. , 2012, Rheumatology.

[16]  D. Danda,et al.  Pneumorrhachis and pneumomediastinum in connective tissue disease-related interstitial lung disease: case series from a tertiary care teaching hospital in South India , 2012, Rheumatology International.

[17]  J. Ryu,et al.  Spontaneous pneumomediastinum: analysis of 62 consecutive adult patients. , 2009, Mayo Clinic proceedings.

[18]  P. Ravaud,et al.  Pneumomediastinum in interstitial lung disease associated with dermatomyositis and polymyositis. , 2008, Arthritis and rheumatism.

[19]  D. Kurosaka,et al.  Pneumomediastinum in dermatomyositis itself is not a poor prognostic factor: report of a case and review of the literature , 2008, Rheumatology International.

[20]  T. Takeuchi,et al.  Combination therapy with corticosteroids, cyclosporin A, and intravenous pulse cyclophosphamide for acute/subacute interstitial pneumonia in patients with dermatomyositis. , 2005, The Journal of rheumatology.

[21]  Kunihiro Yagihashi,et al.  Thin-section CT assessment of spontaneous pneumomediastinum in interstitial lung disease: Correlation with serial changes in lung parenchymal abnormalities☆ , 2005, Respiratory Medicine.

[22]  S. Ito,et al.  A case of dermatomyositis complicated with pneumomediastinum successfully treated with cyclosporin A , 2003, Clinical Rheumatology.

[23]  R. Sontheimer.  Dermatomyositis: an overview of recent progress with emphasis on dermatologic aspects. , 2002, Dermatologic clinics.

[24]  N. Miyasaka,et al.  [A case of dermatomyositis complicated with pneumomediastinum that was successfully treated with cyclosporin A]. , 2001, Ryumachi. [Rheumatism].

[25]  B. V. van Engelen,et al.  Dermatomyositis with subclinical myositis and spontaneous pneumomediastinum with pneumothorax: case report and review of the literature. , 1998, Clinical and experimental rheumatology.

[26]  F. Martinez,et al.  Thin-section CT obtained at 10-mm increments versus limited three-level thin-section CT for idiopathic pulmonary fibrosis: correlation with pathologic scoring. , 1997, AJR. American journal of roentgenology.

[27]  F. Cicuttini,et al.  Recurrent pneumomediastinum in adult dermatomyositis. , 1989, The Journal of rheumatology.

[28]  T. Mimori,et al.  [Anti-MDA5 (melanoma differentiation-associated gene 5) antibody and dermatomyositis with rapidly progressive interstitial pneumonia]. , 2013, Nihon Rinsho Men'eki Gakkai kaishi = Japanese journal of clinical immunology.

[29]  M. Yamakido,et al.  Dermatomyositis associated with rapidly progressive fatal interstitial pneumonitis and pneumomediastinum. , 1999, Scandinavian journal of rheumatology.